SAB BIOTHERAPEUTICS INC (SABS)
Health Care · Clinical-stage biopharmaceuticals / polyclonal antibody therapeutics · NASDAQ
SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1 diabetes.
What SAB BIOTHERAPEUTICS INC does
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, fully human immunoglobulin G (hIgG) antibodies to treat and prevent immune and autoimmune disorders. The company's proprietary Tc-Bovine (transchromosomic cattle) platform produces disease-targeted polyclonal human antibodies without requiring human plasma donors or convalescent plasma. The lead candidate, SAB-142, is a human anti-thymocyte globulin (hATG) in Phase 2b development for autoimmune type 1 diabetes (T1D), designed to slow disease progression and preserve insulin-producing beta cells.
Themes: ["Type 1 diabetes (T1D) / autoimmune disease","Polyclonal antibody therapeutics","Immunotherapy / immune modulation"]
Fundamentals
- Price$3.96 as of 2026-07-09 close
- Market cap$288M as of 2026-07-10
- 1-year return+46.1% as of 2026-07-09 close
- P/E21.72 as of 2026-07-10
- Net margin-1795.8% as of 2026-07-10
- ROE+15.2% as of 2026-07-10
- Debt / equity0.01 as of 2026-07-10
- Beta0.56 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: SAB-142 is still in Phase 2b (SAFEGUARD) trials; failure to meet efficacy or safety endpoints could delay or derail regulatory approval","Regulatory pathway risk: Polyclonal antibodies (pAbs) follow a different regulatory path (CBER vs. CDER) than monoclonal antibodies; any adverse precedent or regulatory change could impact approval timeline","Financial sustainability risk: Company is unprofitable with significant R&D spending (Q1 2026: $13.4M) and limited runway; dependence on capital markets for funding clinical programs"]
Competitors & peers
- Thymoglobulin / Genzyme (rabbit ATG, the established clinical comparator)
- Sanofi (owns Genzyme/Thymoglobulin)
- Regeneron Pharmaceuticals (immune/autoimmune antibodies)
- Momenta Pharmaceuticals (polyclonal and antibody therapeutics)
- Vertex Pharmaceuticals (cell therapy and immune disorders)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.